Hydrochlorothiazide (HCTZ) is linked to a small but real increased risk of non-melanoma skin cancer, particularly squamous cell carcinoma. In 2020, the FDA updated the drug’s label to reflect this risk, estimating roughly one additional case of squamous cell carcinoma per 16,000 patients per year. The risk grows with higher cumulative doses taken over many years, so short-term or low-dose use carries far less concern than decades of daily use.
Which Cancers Are Linked to HCTZ
The connection is specific to non-melanoma skin cancers: squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). SCC shows the stronger association. A 2019 meta-analysis found that thiazide diuretic use was tied to an adjusted odds ratio of 1.86 for SCC and 1.19 for BCC, meaning the relative increase in risk was more pronounced for squamous cell cancers.
There is no established link between HCTZ and internal organ cancers. The concern is confined to the skin, which makes sense given the drug’s mechanism of action (more on that below).
Melanoma is a different story, and it may not follow the same pattern at all. A large retrospective study from South Korea covering over 3 million patients found that HCTZ users actually had a lower risk of melanoma compared to non-users. High cumulative doses were associated with an even greater reduction. The researchers suggested HCTZ might have a protective effect against melanoma, though this finding hasn’t been confirmed across populations. Most of the concern from European and American regulators centers on non-melanoma skin cancers specifically.
Cumulative Dose Matters Most
The risk from HCTZ is not about taking a single pill or even using the medication for a few months. It scales with how much of the drug you’ve taken over your lifetime. A study published in Acta Dermato-Venereologica tracked patients and defined “high cumulative use” as 5,000 or more defined daily doses, which translates to roughly 125,000 milligrams total. At a common daily dose of 25 mg, that threshold would take about 13 to 14 years of continuous use to reach.
Among patients who crossed that threshold, the numbers were striking. The adjusted hazard ratio for basal cell carcinoma was 7.72, and for squamous cell carcinoma it was 19.63. In plainer terms, high-cumulative-dose users had roughly 8 times the risk of BCC and nearly 20 times the risk of SCC compared to those who took less. A separate Danish study set an even higher threshold of 200,000 mg cumulative use and found an adjusted odds ratio of 7.38 for SCC at that level.
These relative risk numbers sound alarming, but context matters. The baseline rate of squamous cell carcinoma is low, so even a large relative increase translates to a modest absolute increase. The FDA’s own analysis landed on approximately one extra case per 16,000 patients per year. If you’ve been on HCTZ for only a year or two, your added risk is negligible.
Why HCTZ Affects the Skin
HCTZ is a photosensitizer, meaning it makes your skin more vulnerable to ultraviolet light. The drug absorbs energy from both UVA and UVB rays and transfers that energy into surrounding tissue, including DNA. This creates reactive oxygen species (essentially, unstable molecules that damage cells) and can directly harm DNA strands.
Research using human skin biopsies showed that when HCTZ is present in the skin, even low-dose UVA exposure activates p53, a protein the body uses to detect and respond to DNA damage. Higher UVA doses in the presence of HCTZ triggered actual DNA damage along with inflammatory responses. Both DNA damage and chronic inflammation are known contributors to cancer development over time. This explains why the risk is concentrated in the skin rather than internal organs: HCTZ accumulates in skin tissue and amplifies the damage from ordinary sun exposure.
Putting the Risk in Perspective
One additional squamous cell carcinoma case per 16,000 patients per year is genuinely small. For comparison, fair-skinned people who spend significant time in the sun without protection face a far higher baseline risk of skin cancer from UV exposure alone. HCTZ adds an incremental layer on top of that existing risk.
The people most affected are those who have taken HCTZ for a decade or longer, have fair skin, have a personal or family history of skin cancer, or spend substantial time outdoors. If several of those factors apply to you, the cumulative effect is more meaningful. If you’ve been on a low dose for a few years and have darker skin, the added risk is very small.
It’s also worth noting that HCTZ remains one of the most commonly prescribed blood pressure medications in the world. Regulators in both the U.S. and Europe reviewed the evidence and chose to add label warnings rather than restrict the drug, reflecting their judgment that the benefits for blood pressure control generally outweigh this particular risk.
Other Thiazide Diuretics
The photosensitizing effect is not unique to HCTZ, but HCTZ has been studied far more than alternatives like chlorthalidone or indapamide. Most of the large observational studies that flagged skin cancer risk focused specifically on HCTZ or grouped all thiazide-type diuretics together without separating them cleanly. There isn’t strong evidence yet showing that switching from HCTZ to chlorthalidone or indapamide eliminates the risk entirely, nor is there clear evidence that those alternatives carry the same degree of risk. If this concern is relevant to you, it’s a reasonable conversation to have with whoever manages your blood pressure medication.
Protecting Yourself While Taking HCTZ
The FDA’s updated labeling specifically recommends that HCTZ users protect their skin from the sun and get regular skin cancer screenings. In practical terms, this means wearing sunscreen with broad-spectrum protection daily, especially on your face, ears, neck, and hands. Protective clothing, hats, and avoiding prolonged midday sun exposure all reduce the UV damage that HCTZ amplifies.
Regular skin checks are particularly important for long-term users. Squamous cell carcinoma typically appears as a firm, red nodule or a flat sore with a scaly crust, often on sun-exposed areas like the face, ears, or backs of the hands. Basal cell carcinoma usually looks like a pearly or waxy bump, or a flat, flesh-colored lesion. Catching either one early leads to straightforward treatment with excellent outcomes. The danger from these cancers comes primarily from ignoring them, not from their inherent aggressiveness.
If you’ve been on HCTZ for many years and have never had a full skin exam, getting one is a simple, practical step that directly addresses the risk the research has identified.